Trium Capital LLP Buys New Holdings in AstraZeneca PLC (NASDAQ:AZN)

Trium Capital LLP acquired a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 102,641 shares of the company's stock, valued at approximately $7,544,000. AstraZeneca accounts for 0.9% of Trium Capital LLP's holdings, making the stock its 11th biggest holding.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company's stock worth $379,000 after purchasing an additional 2,789 shares during the period. Victory Capital Management Inc. increased its holdings in AstraZeneca by 53.9% during the 4th quarter. Victory Capital Management Inc. now owns 404,070 shares of the company's stock worth $26,475,000 after purchasing an additional 141,517 shares during the period. Proficio Capital Partners LLC increased its holdings in AstraZeneca by 5.9% during the 4th quarter. Proficio Capital Partners LLC now owns 10,806 shares of the company's stock worth $708,000 after purchasing an additional 598 shares during the period. Sowell Financial Services LLC purchased a new stake in AstraZeneca during the 4th quarter worth about $1,026,000. Finally, American Assets Inc. purchased a new stake in AstraZeneca during the 4th quarter worth about $426,000. Hedge funds and other institutional investors own 20.35% of the company's stock.

Analysts Set New Price Targets

Separately, BNP Paribas started coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $85.00.

AstraZeneca Stock Performance

Shares of AZN stock traded up $1.06 during trading hours on Thursday, reaching $71.88. 2,380,012 shares of the company's stock were exchanged, compared to its average volume of 5,256,573. The company has a market cap of $222.92 billion, a P/E ratio of 28.87, a price-to-earnings-growth ratio of 1.29 and a beta of 0.37. The company's 50 day moving average is $70.72 and its two-hundred day moving average is $70.71. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.14. The firm had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. AstraZeneca's quarterly revenue was up 7.2% on a year-over-year basis. During the same period last year, the business posted $2.06 EPS. Equities research analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.